IMerge is a Phase 2/3 clinical trial evaluating imetelstat as a treatment for patients with lower risk myelodysplastic syndromes (MDS)that are non-del(5q), dependent on red blood cell transfusion, and are relapsed after or refractory to treatment with erythropoiesis stimulating agents.
The primary efficacy endpoint of IMerge is 8-week red blood cell transfusion independence (RBC-TI) rate, defined as the proportion of patients not receiving any RBC transfusion during any consecutive eight weeks since entry into the trial.
This presentation reports long-term efficacy and safety data from 38 patients in the IMerge phase 2 clinical trial, based on a February 4, 2020 cut-off date and a
median follow-up of 24 months:
• 16 patients (42%) achieved 8-week RBC-TI, and 12 of these responders (75%) showed a haemoglobin rise of > 3 g/dL compared to pretreatment during the transfusion-free interval
• 12 patients (32%) achieved a 24-week RBC-TI
• 11 patients (29%) were transfusion-free for more than one year; the longest transfusion-free
interval was 2.7 years
• Median RBC-TI duration was 88 weeks, the longest reported to date in non-del(5q) LR MDS
• Haematologic improvement-erythroid was achieved by 26 patients (68%) with a median
duration of 93 weeks
• Durability of TI, cytogenetic and mutational malignant clone reduction in some patients
indicates potential disease-modifying activity of imetelstat
• Most frequently reported adverse events were manageable and reversible grade > 3
cytopenias
The phase 3 double-blind, placebo-controlled stage of IMerge is currently recruiting patients and is ongoing.
Source: EHA
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.